Kenneth Chien

Kenneth Chien is a cardiovascular scientist and professor at Harvard Medical School and the Massachusetts General Hospital who was recruited by Derrick Rossi to join the founding team based on his expertise in cardiovascular biology and drug development. Chien's research focused on cardiac stem cells and regenerative medicine, and he recognized that mRNA could be used to produce therapeutic proteins for cardiovascular diseases including heart failure and ischemic heart disease. Chien's involvement provided scientific credibility in the cardiovascular therapeutic area, which was one of Moderna's initial focus areas. His decision to join the founding team reflected his belief that mRNA technology could address the fundamental challenge of protein replacement therapy for genetic cardiovascular diseases. The founder's contributions to Moderna exemplify the intersection of academic research, venture capital, and entrepreneurial vision that drives biotechnology innovation.

Kenneth Chien served as a co-founder and early scientific advisor to Moderna, contributing to the company's initial pipeline strategy in cardiovascular and rare disease therapeutics. Chien later departed from day-to-day involvement but remained a shareholder. His scientific contributions to cardiovascular biology have been recognized through numerous awards and leadership positions, including founding director of the Harvard Stem Cell Institute Cardiovascular Program. Chien's involvement in Moderna's founding illustrates how academic scientists with domain expertise can translate their research into commercial ventures when combined with platform technology and entrepreneurial leadership. His continued support for the company reflects his belief in the long-term potential of mRNA therapeutics for cardiovascular disease. The founder's ongoing involvement with Moderna reflects a commitment to the company's mission of transforming mRNA science into medicines that improve human health.